JP2024507275A5 - - Google Patents

Info

Publication number
JP2024507275A5
JP2024507275A5 JP2023551145A JP2023551145A JP2024507275A5 JP 2024507275 A5 JP2024507275 A5 JP 2024507275A5 JP 2023551145 A JP2023551145 A JP 2023551145A JP 2023551145 A JP2023551145 A JP 2023551145A JP 2024507275 A5 JP2024507275 A5 JP 2024507275A5
Authority
JP
Japan
Prior art keywords
composition according
antibody
composition
icam1
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017499 external-priority patent/WO2022182743A1/en
Publication of JP2024507275A publication Critical patent/JP2024507275A/ja
Publication of JP2024507275A5 publication Critical patent/JP2024507275A5/ja
Pending legal-status Critical Current

Links

JP2023551145A 2021-02-23 2022-02-23 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用 Pending JP2024507275A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152747P 2021-02-23 2021-02-23
US63/152,747 2021-02-23
PCT/US2022/017499 WO2022182743A1 (en) 2021-02-23 2022-02-23 Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof

Publications (2)

Publication Number Publication Date
JP2024507275A JP2024507275A (ja) 2024-02-16
JP2024507275A5 true JP2024507275A5 (enExample) 2025-03-05

Family

ID=83048467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551145A Pending JP2024507275A (ja) 2021-02-23 2022-02-23 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用

Country Status (5)

Country Link
US (1) US20240148888A1 (enExample)
EP (1) EP4297783A4 (enExample)
JP (1) JP2024507275A (enExample)
CA (1) CA3211696A1 (enExample)
WO (1) WO2022182743A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012002388A1 (ja) * 2010-07-01 2013-08-29 国立大学法人信州大学 センチネルリンパ節への薬物輸送剤
CA2921982C (en) * 2013-09-02 2020-08-25 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
AU2014337555C1 (en) * 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
US20170173005A1 (en) * 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
EP3317246A4 (en) * 2015-07-04 2019-02-27 Suzhou M-conj Biotech Co., Ltd. SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE
CA3151800A1 (en) * 2019-08-23 2021-03-04 Children's Medical Center Corporation Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof

Similar Documents

Publication Publication Date Title
Alley et al. Antibody–drug conjugates: targeted drug delivery for cancer
Jeffrey et al. Dipeptide-based highly potent doxorubicin antibody conjugates
Teicher et al. Antibody conjugate therapeutics: challenges and potential
AU2016216585B2 (en) Drug conjugate composition
JP2022546387A5 (enExample)
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Jackson et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates: Jackson and Stover
JP2017514905A5 (enExample)
JP2024525624A5 (enExample)
HRP20150806T1 (hr) Protutijela anti-cd22, njihovi imunokonjugati kao i njihove uporabe
JP2020526584A5 (enExample)
JP2025183203A5 (enExample)
AU2014337555B2 (en) PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
CN111655295A (zh) 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
JP2023546493A5 (enExample)
ZA202211455B (en) Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination
Abbas et al. Antibody‐Drug Conjugates Used in Breast Cancers
Singh et al. Antibody‐Drug Conjugates: New Frontier in Cancer Therapeutics
JPWO2023190827A5 (enExample)
Senter et al. Monoclonal antibody drug conjugates for cancer therapy
JP2025514287A5 (enExample)
RU2024129146A (ru) pH-ЗАВИСИМОЕ АНТИТЕЛО К СУЛЬФАТИРОВАННОМУ ГЛИКОЗАМИНОГЛИКАНУ И КОНЪЮГАТ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО
HK1153942A (en) Drug conjugate composition
HK1153942B (en) Drug conjugate composition